![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/PXP34CHOIBTL2DNV5SD6AEUBFQ.jpg?smart=true&auth=9d5acb67dc3eb3070ca1339668ea2efd2d0357aa7308cb4508dc2f3cf42321ff&width=400&height=225)
G42 has branched out into testing, vaccine production and vaccine trials, among other fields. Victor Besa / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/RINUI7ZFLL5G5PEA7PXMWP57QY.jpg?smart=true&auth=3a3d09aa8cdb26c6799d72fa7d8ac2ba56be45436aa2851b1c2d80896817e487&width=400&height=225)
Bottles move along a production line at Julphar's manufacturing facility in Ras Al Khaimah in this file image. The company is already producing the Sinopharm vaccine and will be part of a plan to build a dedicated plant in Abu Dhabi's Kizad zone. Pawan Singh / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/CD4S5266SIKXMCN62FYUDJT4XU.jpg?smart=true&auth=eb35f06653b2730217164435e30218974f0740560f8bd93a76dae473d72383d4&width=400&height=225)
Inside view of the manufacturing area at Gulf Pharmaceutical Industries in Ras Al Khaimah, in a file image. Pawan Singh / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/IU6PFKN34LKR46CAYE2MHUQX5I.jpg?smart=true&auth=fbb6b1f493a2a08634056544ec1d65a9d50edc28325e86d93fc97f25e6cb68e5&width=400&height=225)
Staff from Abu Dhabi's G42 undergo testing at the company's Biogenix lab in Masdar City. The firm outlined a plan to create 200 million doses of China's Sinopharm vaccine under the name Hayat-Vax, at a new and dedicated plant in Abu Dhabi's Kizad. Victor Besa / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/7WJLOJWUIOWEX6EAOPNOYDCVS4.jpg?smart=true&auth=04b48509c327ffa430aad7fc1e72ab7e0e6b58923aa733afdc3cb424b63b618c&width=400&height=225)
Dr Nawal Al Kaabi, principle investigator of Phase 3 clinical trials of Sinopharm and Ashish Koshy, CEO of G42 Healthcare, speak to The National in January. The successful trials paved the way for the vaccine to be approved, and now produced, in the UAE. Victor Besa / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/3SZZEOMFVJSVIV2G3V6XENTUW4.jpg?smart=true&auth=a3392c4e4c658972c88437cbf71e54bcfc4935b8351839aad45ced246761fb3b&width=400&height=225)
Ashish Koshy said the UAE wants to ensure that vaccines are made from start to finish in the emirates. Vidhyaa Chandramohan for The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/42X64CZAGRMK2OR6RBCRTT5XSY.jpg?smart=true&auth=170d4b882a0af86f6157bf91bc038c22fbea1ee25906cd2757daed1c3482dbbf&width=400&height=225)
An Abu Dhabi resident waves as he is processed for a PCR test at G42 Healthcare's Biogenix lab in Masdar City. The company, together with Ras Al Khaimah drug maker Julphar, have begun manufacturing China's Sinopharm vaccine in the UAE. Victor Besa / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/AYR6AKRASKNVZ5CRGP3XWZ7OQE.jpg?smart=true&auth=dbbe84c8398a5ac91a7aac2f48878aeba1c880158baa591e5a78ebdede209afe&width=400&height=225)
A healthcare worker holds up saliva sample vials at the Biogenix lab at G42 in Masdar City. Victor Besa / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/PXP34CHOIBTL2DNV5SD6AEUBFQ.jpg?smart=true&auth=9d5acb67dc3eb3070ca1339668ea2efd2d0357aa7308cb4508dc2f3cf42321ff&width=400&height=225)
G42 has branched out into testing, vaccine production and vaccine trials, among other fields. Victor Besa / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/RINUI7ZFLL5G5PEA7PXMWP57QY.jpg?smart=true&auth=3a3d09aa8cdb26c6799d72fa7d8ac2ba56be45436aa2851b1c2d80896817e487&width=400&height=225)
Bottles move along a production line at Julphar's manufacturing facility in Ras Al Khaimah in this file image. The company is already producing the Sinopharm vaccine and will be part of a plan to build a dedicated plant in Abu Dhabi's Kizad zone. Pawan Singh / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/CD4S5266SIKXMCN62FYUDJT4XU.jpg?smart=true&auth=eb35f06653b2730217164435e30218974f0740560f8bd93a76dae473d72383d4&width=400&height=225)
Inside view of the manufacturing area at Gulf Pharmaceutical Industries in Ras Al Khaimah, in a file image. Pawan Singh / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/IU6PFKN34LKR46CAYE2MHUQX5I.jpg?smart=true&auth=fbb6b1f493a2a08634056544ec1d65a9d50edc28325e86d93fc97f25e6cb68e5&width=400&height=225)
Staff from Abu Dhabi's G42 undergo testing at the company's Biogenix lab in Masdar City. The firm outlined a plan to create 200 million doses of China's Sinopharm vaccine under the name Hayat-Vax, at a new and dedicated plant in Abu Dhabi's Kizad. Victor Besa / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/7WJLOJWUIOWEX6EAOPNOYDCVS4.jpg?smart=true&auth=04b48509c327ffa430aad7fc1e72ab7e0e6b58923aa733afdc3cb424b63b618c&width=400&height=225)
Dr Nawal Al Kaabi, principle investigator of Phase 3 clinical trials of Sinopharm and Ashish Koshy, CEO of G42 Healthcare, speak to The National in January. The successful trials paved the way for the vaccine to be approved, and now produced, in the UAE. Victor Besa / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/3SZZEOMFVJSVIV2G3V6XENTUW4.jpg?smart=true&auth=a3392c4e4c658972c88437cbf71e54bcfc4935b8351839aad45ced246761fb3b&width=400&height=225)
Ashish Koshy said the UAE wants to ensure that vaccines are made from start to finish in the emirates. Vidhyaa Chandramohan for The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/42X64CZAGRMK2OR6RBCRTT5XSY.jpg?smart=true&auth=170d4b882a0af86f6157bf91bc038c22fbea1ee25906cd2757daed1c3482dbbf&width=400&height=225)
An Abu Dhabi resident waves as he is processed for a PCR test at G42 Healthcare's Biogenix lab in Masdar City. The company, together with Ras Al Khaimah drug maker Julphar, have begun manufacturing China's Sinopharm vaccine in the UAE. Victor Besa / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/AYR6AKRASKNVZ5CRGP3XWZ7OQE.jpg?smart=true&auth=dbbe84c8398a5ac91a7aac2f48878aeba1c880158baa591e5a78ebdede209afe&width=400&height=225)
A healthcare worker holds up saliva sample vials at the Biogenix lab at G42 in Masdar City. Victor Besa / The National
![](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/PXP34CHOIBTL2DNV5SD6AEUBFQ.jpg?smart=true&auth=9d5acb67dc3eb3070ca1339668ea2efd2d0357aa7308cb4508dc2f3cf42321ff&width=400&height=225)
G42 has branched out into testing, vaccine production and vaccine trials, among other fields. Victor Besa / The National
Hayat-Vax: UAE drug firm already making Sinopharm vaccine under new name
Julphar can produce 2 million doses per month, with a dedicated vaccine plant at Abu Dhabi's Kizad in the works to boost that figure
![Rory Reynolds](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/https%3A%2F%2Fs3.amazonaws.com%2Farc-authors%2Fthenational%2F4fce2028-52ba-44a8-aecb-4cd66a2a09ce.png?smart=true&auth=ee54aa3318d6a60c21790f46263953f5fdf327dd968be815cc23275b290bd5f5&width=70&height=70)
Rory Reynolds
29 March, 2021
- Listen In English
- Listen In Arabic